Rachel is an Intellectual Property / Patent Litigation Partner at HGF and has worked with clients across a broad range of sectors. With her background in cell biotechnology, Rachel’s work has a particular focus on the life sciences, biotechnology, pharmaceuticals (small and large drug molecules), healthcare and chemicals industries, as well as advising clients in the advanced engineering and electronics sectors.
Rachel has extensive experience of litigating before the UK Patents Court, High Court and Court of Appeal as well as advising in opposition proceedings before the UKIPO, EPO and OHIM. Rachel regularly coordinates complex, multi-jurisdictional IP litigation strategy, supporting and advising clients to achieve an effective IP strategy across all commercially important jurisdictions.
Rachel has been involved in a number of decided cases before the Patents Court including: Accord Healthcare Ltd v Research Corporation Technologies, Inc.  R.P.C. 4; Nestec SA v Dualit Ltd  R.P.C. 32; Virgin Atlantic Airways v Air Canada & ors,  R.P.C. 10; Appeal  R.P.C 18; Actavis UK Ltd v Novartis AG  EWHC 41 (Ch); Actavis UK Ltd v Novartis AG  F.S.R. 18; Actavis UK Ltd v Eli Lilly & Co Ltd  EWCA Civ 43; Baxter Healthcare Corporation v Abbott Laboratories  EWHC 3185 (Pat); and Ranbaxy UK Ltd v Warner-Lambert Co.  F.S.R. 14.
Rachel joined HGF in 2015 after training and working at a leading international IP litigation practice for over 10 years. Rachel has a BSc in Cell Biotechnology from the University of Alberta, Canada and a Masters in Health Care Ethics from the University of Leeds. Rachel completed her Postgraduate Diploma in Law and LPC at the College of Law and a Postgraduate Diploma in Intellectual Property at the University of Bristol.